Loading
Epetraborole is an experimental pill from AN2 Therapeutics, with a phase 2 trial due to start for polycythaemia vera.
Epetraborole (EBO) is a small molecule, oral (boron-based) from AN2 Therapeutics. The company says it acts on globin synthesis to lower the haematocrit, selectively in red cells, rather than suppressing blood cell production broadly. Its cancer use is polycythaemia vera only: a phase 2 study (NCT07891533) is due to start in November 2026. AN2 also studies it in lung infections that are not cancer (Mycobacterium abscessus lung disease and melioidosis).
The company says it acts on globin synthesis to lower the haematocrit, selectively in red cells, rather than suppressing blood cell production broadly.
1.Epetraborole slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Epetraborole" OR ABSTRACT:"Epetraborole") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Epetraborole, not a curated reading list.
Shares Polycythaemia vera (PV) and the tag pipeline.
Shares Polycythaemia vera (PV) and the tag pipeline.
Shares Polycythaemia vera (PV) and the tag pipeline.
Shares Polycythaemia vera (PV) and the tag pipeline.
Shares Polycythaemia vera (PV) and the tag pipeline.
Shares Polycythaemia vera (PV) and the tag pipeline.
Shares Polycythaemia vera (PV) and the tag pipeline.
Shares Polycythaemia vera (PV) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/